MedTrace Logo

The Post-Vitrectomy Lenstatin™ Study

NCT02131194 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-12-04

No results posted yet for this study

Summary

To determine the efficacy of Lenstatin™, an over-the-counter nutritional supplement, in inhibiting the progression of nuclear cataract in eyes after pars plana vitrectomy.

Conditions

  • Cataract, Nuclear Progressive

Interventions

DIETARY_SUPPLEMENT

Lenstatin

Dietary Supplement Lenstatin

DRUG

Placebo

Placebo sugar pill manufactured to mimic Lenstatin

Sponsors & Collaborators

  • Lenstatin LLC

    lead INDUSTRY

Principal Investigators

  • Scott W Tunis, MD FACS · Lenstatin LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02131194 on ClinicalTrials.gov